Altrubio Inc. secured up to $225 million in an oversubscribed series B financing round, led by BVF Partners LP. The full amount is dependent on Altrubio meeting certain undisclosed milestones. New investors RA Capital Management, Cormorant Asset Management and Soleus Capital, and existing investors Amoon Fund and Blackstone Multi-Asset Investing, as well as other new and existing investors, also participated in the financing round.

Biopharmas raising money in public or private financings, including: Dyne, GT, Mymd, Progentos, Ygion.

Med-tech firms raising money in public or private financings, including: Vantis.

Biopharmas in Asia-Pacific raising money in public or private financings: Telix.

Ygion Biomedical GmbH has completed a series A financing round of €15 million (US$ 16.3 million) to support the development of individualized neoantigen-based cancer vaccines.

Progentos Therapeutics Inc. has announced its launch and the closing of a $65 million series A round.

Biopharmas raising money in public or private financings, including: Amplexd, Briacell, Coya, Foghorn, Inhibikase, Polarityte, Rapport, Virios.

Med-tech firms raising money in public or private financings, including: Polarityte, T2 Biosystems.